On target management for secondary hyperparathyroidism by two calcimimetics (HP2C study)

On target management for secondary hyperparathyroidism by two calcimimetics (HP2C study) - HP2C study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029000

Enrollment

300

Registered

2017-10-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

According to the clinical practice guideline for the management of chronic kidney disease-meneral and bone disease (JSDT 2012), treated with intravenous calcimimetics (etelcalcetide) for 1 year. Accor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Maintenance hemodialysis patients with secondary hyperparathyroidism (int-PTH>240 pg/mL)

Exclusion criteria

Exclusion criteria: Patients with sever heart failure (>NYHA III),liver dysfunction, respiratory failure, and malignant tumor.

Design outcomes

Primary

Measure	Time frame
Achievement ratio for target levels of PTH, Ca, and P.	—

Secondary

Measure	Time frame
1) Bone metabolism marker. 2) Bone density. 3) Intestinal bacteria. 4) Arteriosclerosis index. 5) Drugs. 6) Anemia and iron-related factor. 7) The taking medicine situation. 8) Symptom. 9) Medical economic effect.	—

Countries

Japan

Contacts

Public ContactTakahiro Kuragano

Hyogo College of Medicine Department of Internal Medicine, Division of Kidney and dialysis

kuragano@hyo-med.ac.jp0798-45-6521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026